Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Breast Neoplasms 17Colorectal Neoplasms 6Stomach Neoplasms 4HER2-positive Breast Cancer 4Carcinoma, Non-Small-Cell Lung 3Brain Neoplasms 3Neoplasms 2Adenocarcinoma Of Esophagus 2Uterine Neoplasms 1Uterine Cervical Neoplasms 1Urologic Neoplasms 1Triple Negative Breast Neoplasms 1Ovarian Neoplasms 1Neoplasms by Site 1HER2-positive Metastatic Breast Cancer 1HER2-positive Gastric Cancer 1Gallbladder Neoplasms 1Esophageal Neoplasms 1Cholangiocarcinoma 1Breast Diseases 1Biliary Tract Neoplasms 1Advanced Unresectable or Metastatic Solid Malignancy 1

Interventions

Gemcitabine 28pembrolizumab 24Cisplatin 24Fluorouracil 11Leucovorin 10Oxaliplatin 8Nivolumab 7Capecitabine 6Irinotecan 5Drug Therapy 5pemigatinib 4futibatinib 4Paclitaxel 4Carboplatin 4ivosidenib 3durvalumab 3derazantinib 3Folfox protocol 3Bevacizumab 3zanidatamab 2spartalizumab 2olutasidenib 2lenvatinib 2infigratinib 2fludarabine 2budigalimab 2Trastuzumab 2Ipilimumab 2Injections 2Docetaxel 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Cholangiocarcinoma × tucatinib × Clear all
NCT04430738 2026-02-24

Tucatinib Plus Trastuzumab and Oxaliplatin-based Chemotherapy or Pembrolizumab-containing Combinations for HER2+ Gastrointestinal Cancers

Seagen Inc.

Phase 2 Active not recruiting
40 enrolled 67 charts
Gastrointestinal

Adenocarcinoma Of Esophagus, Esophageal Neoplasms, Gallbladder Neoplasms, Stomach Neoplasms, Colorectal Neoplasms, Cholangiocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡